Pure Global
NCT06210230

Double-blind and Placebo-controlled Study on Intervention Effect of Medium and Long Chain Fatty Acid Triglyceride on Glycolipid Homeostasis in Patients With Metabolic Syndrome and Mechanisms

Zhejiang University·ClinicalTrials.gov·dietary supplementCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Metabolic Syndrome
Drug/Device/Intervention
MLCT supplementation
Study type
Interventional
Intervention type
dietary supplement
Sponsor & location
Primary sponsor
Zhejiang University
Location
Jinhua, China
Timeline & enrollment
Phase
N/A
Start date
May 22, 2023
End date
Dec 10, 2023
Enrollment
240 participants
Primary outcome

Change in blood glucose from baseline,Change in blood lipids from baseline

Summary

Double-blind and placebo-controlled study on intervention effect of medium and long chain
 fatty acid triglyceride on glycolipid homeostasis in patients with metabolic syndrome and
 mechanisms

ICD-10 classifications
Metabolic disordersMetabolic disorder, unspecifiedOther metabolic disordersOther specified metabolic disordersNutritional and metabolic disorders in diseases classified elsewhere
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06210230
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06210230 through Pure Global AI's free database. This phase not specified trial is sponsored by Zhejiang University and is currently Completed. The study focuses on Metabolic Syndrome. Target enrollment is 240 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.